BioLineRx’s (BLRX) “Buy” Rating Reiterated at HC Wainwright

BioLineRx (NASDAQ:BLRX)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $21.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com upgraded BioLineRx to a “sell” rating in a report on Friday, April 12th.

BioLineRx Stock Up 3.0 %

Shares of BioLineRx stock opened at $0.64 on Wednesday. The stock’s 50-day moving average is $1.07 and its 200 day moving average is $1.34. The firm has a market cap of $51.17 million, a price-to-earnings ratio of -0.71 and a beta of 1.38. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.53 and a quick ratio of 1.47. BioLineRx has a one year low of $0.61 and a one year high of $2.53.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. The firm had revenue of $4.80 million during the quarter, compared to the consensus estimate of $0.17 million. During the same quarter in the previous year, the company posted ($0.09) EPS. Equities research analysts anticipate that BioLineRx will post -1.03 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. NorthRock Partners LLC bought a new position in shares of BioLineRx in the fourth quarter valued at approximately $27,000. B. Riley Wealth Advisors Inc. lifted its holdings in shares of BioLineRx by 88.5% in the third quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 10,000 shares in the last quarter. Allen Mooney & Barnes Investment Advisors LLC bought a new position in shares of BioLineRx in the third quarter valued at approximately $46,000. Renaissance Technologies LLC lifted its holdings in shares of BioLineRx by 49.1% in the third quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 22,478 shares in the last quarter. Finally, LPL Financial LLC increased its position in shares of BioLineRx by 152.7% during the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 71,134 shares during the last quarter. Institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.